6505-- Denosumab Injections

The Department of Veterans Affairs National Acquisition Center is soliciting proposals for the supply of Denosumab Injections in two strengths: 60MG (estimated 22,737 units annually) and 120MG (estimated 5,472 units annually). The contract is a firm fixed price, indefinite-delivery requirements arrangement for a base year plus four one-year optional ordering periods, with pricing distributed through government Pharmaceutical Prime Vendor (PPV) contractors serving VA facilities, Department of Defense, Indian Health Service, Bureau of Prisons, and Federal Health Care Centers. Offerors must demonstrate FDA approval and current acceptable Good Manufacturing Practice (cGMP) status at all manufacturing and packaging facilities, provide unique 11-digit National Drug Code (NDC) numbers specific to their company, comply with Drug Supply Chain Security Act requirements including GS1 data matrix barcoding, and include a 0.5% Cost Recovery Fee in all quoted prices. Award will be made to the lowest-priced technically acceptable offer, with offerors required to submit prices for the base year and all four option years to be considered. Proposals are due April 28, 2026, at 2:30 PM Central Time, and must be submitted via email to Raymond.roldan@va.gov and Nicholas.mcgregor@va.gov with a signed, scanned SF-1449 form.

This solicitation includes no set-aside designations and has no identified incumbent contractors. While specific budget information is not disclosed in the solicitation documents, the estimated annual volume of approximately 28,209 total units provides a basis for cost projections over the five-year contract period. Non-small business concerns valued over $900,000 must submit an approved subcontracting plan with goals for service-disabled veteran-owned and veteran-owned small business subcontracting. The contract establishes nationwide pricing for government use, with the awarded contractor required to establish business-to-business agreements with PPV distributors and ensure product availability within a maximum 60-day implementation period. Manufacturing location changes require prior Contracting Officer approval following FDA cGMP verification, and contractors must immediately notify the government of any FDA violations or warning letters, with corrective action required within 90 calendar days.